Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) EBITDA: 2020-2025

Historic EBITDA for GeneDx Holdings (WGS) over the last 6 years, with Sep 2025 value amounting to -$7.4 million.

  • GeneDx Holdings' EBITDA rose 5.20% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 102.62%. This contributed to the annual value of -$51.9 million for FY2024, which is 70.41% up from last year.
  • Per GeneDx Holdings' latest filing, its EBITDA stood at -$7.4 million for Q3 2025, which was down 169.48% from $10.7 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' EBITDA registered a high of $32.7 million during Q3 2021, and its lowest value of -$308.8 million during Q4 2022.
  • Its 3-year average for EBITDA is -$20.9 million, with a median of -$20.4 million in 2024.
  • Its EBITDA has fluctuated over the past 5 years, first spiked by 157.81% in 2021, then crashed by 668.35% in 2022.
  • GeneDx Holdings' EBITDA (Quarterly) stood at -$40.2 million in 2021, then tumbled by 668.35% to -$308.8 million in 2022, then skyrocketed by 91.79% to -$25.3 million in 2023, then surged by 121.11% to $5.3 million in 2024, then grew by 5.20% to -$7.4 million in 2025.
  • Its EBITDA stands at -$7.4 million for Q3 2025, versus $10.7 million for Q2 2025 and -$6.5 million for Q1 2025.